This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
The Washington Post
washingtonpost.com
did:plc:k5nskatzhyxersjilvtnz4lh
Consumers are turning to cash to pay for GLP-1 weight-loss drugs as demand rises and insurance coverage lags.
Eli Lilly and Novo Nordisk are cutting prices to compete with cheaper compounded versions, which are not FDA-approved.
https://www.washingtonpost.com/health/2026/03/12/weight-loss-drugs-price-wegovy-zepbound/?utm_campaign=wp_main&utm_source=bluesky&utm_medium=social
2026-03-13T03:00:08.151Z